Research Article
Exposure to Mebendazole and Pyrvinium during Pregnancy: A Danish Nationwide Cohort Study
Table 2
Predictors of exposure to pyrvinium and mebendazole during pregnancy expressed by odds ratios (OR) and 95% confidence intervals (CI).
| | Pyrvinium versus unexposed OR* (95% CI) | Mebendazole versus unexposed OR* (95% CI) |
| | Age | | | | 20–24 versus <20 | 0.72 (0.47–1.10) | 0.74 (0.48–1.16) | | 25–29 versus <20 | 0.65 (0.42–0.98) | 0.74 (0.48–1.15) | | 30–34 versus <20 | 0.71 (0.47–1.10) | 0.77 (0.50–1.20) | | >35 versus <20 | 0.61 (0.39–0.95) | 0.69 (0.44–1.08) |
| | Income | | | | Quartile 2 versus 1 | 1.03 (0.88–1.19) | 1.15 (1.03–1.30) | | Quartile 3 versus 1 | 1.14 (0.98–1.33) | 1.01 (0.89–1.14) | | Quartile 4 versus 1 | 0.99 (0.84–1.16) | 0.95 (0.84–1.08) |
| | Parity | | | | 1 versus 0 | 2.31 (1.98–2.69) | 4.30 (3.67–5.04) | | 2 versus 0 | 5.38 (4.56–6.35) | 12.70 (10.79–14.94) | | >2 versus 0 | 7.07 (5.75–8.68) | 20.76 (17.31–24.88) |
| | Education | | | | Medium versus low | 1.01 (0.89–1.16) | 1.02 (0.92–1.13) | | High versus low | 1.08 (0.94–1.25) | 1.28 (1.15–1.44) |
| | Smoking | | | | Yes versus no | 0.89 (0.78–1.02) | 0.92 (0.82–1.02) |
|
|
Adjusted for age, income, parity, level of completed education, and smoking.
|
